$-2.37
(Market cap
$22,518 Mln
Revenue (TTM)
$820 Mln
P/E Ratio
--
P/B Ratio
31.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-2.9 %
-
ROCE
-82.2 %
-
Industry P/E
--
-
EV/EBITDA
-6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-5.7
-
Face value
--
-
Shares outstanding
216,752,451
10 Years Aggregate
CFO
$-2,499.40 Mln
EBITDA
$-2,868.26 Mln
Net Profit
$-3,104.72 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Insmed Inc (INSM)
| -33.6 | -23.5 | -22.3 | 76.0 | 83.4 | 35.3 | 26.8 |
|
BSE Sensex*
| -11.1 | -2.1 | -8.9 | -7.5 | 6.6 | 9.1 | 11.4 |
|
S&P 100
| 8.2 | 11.2 | 12.2 | 30.9 | 25.3 | 15.0 | 15.2 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Insmed Inc (INSM)
| 152.1 | 121.3 | 55.1 | -26.7 | -18.2 | 39.4 | 82.0 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Insmed Inc (INSM)
|
115.6 | 22,518.4 | 819.6 | -1,183.8 | -141.4 | -143.4 | -- | 31.2 |
| 293.5 | 38,029.7 | 4,286.9 | 577.2 | 9.8 | 88.2 | 71.4 | 36.6 | |
| 75.7 | 12,457.5 | 1,057.9 | -326.6 | -16.4 | -58.9 | -- | 25.5 | |
| 170.7 | 28,965.5 | 16,632.0 | 1,385.0 | 14.1 | 22.4 | 21.6 | 4.8 | |
| 50.0 | 20,982.1 | 2,225.0 | -3,194.0 | -143.4 | -38.2 | -- | 2.9 | |
| 159.1 | 15,141.8 | 3,102.4 | 668.6 | 27.4 | 20.9 | 23.2 | 4.5 | |
| 712.9 | 74,726.1 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 17.4 | 2.4 | |
| 18.1 | 14,483.2 | 0.0 | -872.2 | -- | -287.7 | -- | 25.7 | |
| 575.8 | 24,189.5 | 3,169.8 | 1,287.4 | 50.7 | 20.6 | 20.9 | 4.1 | |
| 450.4 | 110,448.5 | 12,255.1 | 4,338.3 | 31.7 | 23.7 | 25.8 | 5.6 |
Shareholding Pattern
View DetailsAbout Insmed Inc (INSM)
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial... lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey. Address: 700 US Highway 202/206, Bridgewater, NJ, United States, 08807 Read more
-
President, CEO & Chairman
Mr. William H. Lewis J.D., M.B.A.
-
President, CEO & Chairman
Mr. William H. Lewis J.D., M.B.A.
-
Headquarters
Bridgewater, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Insmed Inc (INSM)
What is the current share price of Insmed Inc (INSM) Today?
The share price of Insmed Inc (INSM) is $115.62 (NASDAQ) as of 14-May-2026 16:00 EDT. Insmed Inc (INSM) has given a return of 83.44% in the last 3 years.
What is the current PB & PE ratio of Insmed Inc (INSM)?
Since, TTM earnings of Insmed Inc (INSM) is negative, P/E ratio is not available.
The P/B ratio of Insmed Inc (INSM) is 31.17 times as on 12-May-2026, a 594 premium to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-29.12
|
50.31
|
|
2024
|
-13.53
|
43.31
|
|
2023
|
-5.99
|
-13.52
|
|
2022
|
-5.51
|
30.14
|
|
2021
|
-7.43
|
7.86
|
What is the 52 Week High and Low of Insmed Inc (INSM)?
The 52-week high and low of Insmed Inc (INSM) are Rs 212.75 and Rs 64.85 as of 15-May-2026.
What is the market cap of Insmed Inc (INSM)?
Insmed Inc (INSM) has a market capitalisation of $ 22,518 Mln as on 12-May-2026. As per SEBI classification, it is a Large Cap company.
Should I invest in Insmed Inc (INSM)?
Before investing in Insmed Inc (INSM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.